

## RESEARCH PAPER

# Regional enhancement of cannabinoid CB<sub>1</sub> receptor desensitization in female adolescent rats following repeated $\Delta^9$ -tetrahydrocannabinol exposure

James J Burston<sup>1,2</sup>, Jenny L Wiley<sup>1,3</sup>, Abimbola A Craig<sup>1</sup>, Dana E Selley<sup>1</sup> and Laura J Sim-Selley<sup>1</sup>

<sup>1</sup>Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA, and <sup>2</sup>Faculty of Health and Life Sciences, University of the West of England Bristol, Coldharbour Lane, Bristol, UK, and

<sup>3</sup>Research Triangle Institute, Research Triangle Park, NC, USA

## BACKGROUND AND PURPOSE

Disruption of the substantial re-organization of the brain during adolescence may be induced by persistent abuse of marijuana. The aim of this study was to determine whether adolescent and adult rats exhibit differential adaptation of brain cannabinoid (CB<sub>1</sub>) receptors after repeated exposure to  $\Delta^9$ -tetrahydrocannabinol (THC).

## EXPERIMENTAL APPROACH

Rats of both ages and sexes were dosed with 10 mg kg<sup>-1</sup> THC or vehicle twice daily for 9.5 days. Subsequently, CB<sub>1</sub> receptor function and density were assessed.

## KEY RESULTS

In all brain regions, THC treatment produced desensitization and down-regulation of CB<sub>1</sub> receptors. While the magnitude of down-regulation did not differ across groups, greater desensitization was evident in the brains of THC-treated female adolescent rats for most regions. Adolescent females showed greater desensitization than adult females in the prefrontal cortex, hippocampus, periaqueductal gray (PAG) and ventral midbrain. In contrast, adolescent males exhibited less desensitization in the prefrontal cortex, hippocampus and PAG, an effect opposite to that seen in females. With the exception of the PAG, sex differences were seen only in adolescents, with greater desensitization in the prefrontal cortex, striatum, hippocampus, PAG, and ventral midbrain of females.

## CONCLUSIONS AND IMPLICATIONS

These results suggest that the brains of adolescent females may be particularly vulnerable to disruption of CB<sub>1</sub> receptor signalling by marijuana abuse. Alternatively, increased desensitization may reflect protective adaptation. Given the extensive re-organization of the brain during adolescence, this disruption has potential long-term consequences for maturation of the endocannabinoid system.

## Abbreviations

2-AG, 2-arachidonylglycerol; CP55,940, (-)-cis-3-[2-hydroxy-4(1,1-dimethyl-heptyl)phenyl]-trans-4-(3-hydroxy-propyl)cyclohexanol; PAG, periaqueductal gray; PN, postnatal day; SR141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl; THC,  $\Delta^9$ -tetrahydrocannabinol; VTA, ventral tegmental area

## Correspondence

Jenny Wiley, Research Triangle Institute, 3040 Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC 27709-2194, USA.  
E-mail: [jwiley@rti.org](mailto:jwiley@rti.org)

## Keywords

adolescence; cannabinoids; [<sup>35</sup>S]GTP $\gamma$ S; receptor binding;  $\Delta^9$ -tetrahydrocannabinol

## Received

9 December 2009

## Revised

15 March 2010

## Accepted

6 April 2010

*BJP* has previously published themed issues on *Cannabinoid Pharmacology* (2007), *CB<sub>2</sub> Receptors* (2008) and *Cannabinoids* (2010). To view these issues visit <http://dx.doi.org/10.1111/bph.2007.152.issue-5>, <http://dx.doi.org/10.1111/bph.2008.153.issue-2> and <http://dx.doi.org/10.1111/bph.2010.160.issue-3>

## Introduction

Marijuana, one of the most commonly used illicit drugs (Copeland and Swift, 2009), is widely used by adolescents and young adults, but its effects on the adolescent brain are not well understood. Use of marijuana and other psychoactive drugs during adolescence is of particular concern due to possible drug-induced disruption of the maturation of the CNS that occurs in this important developmental window (Jager and Ramsey, 2008). Previous studies have indicated that frequent marijuana use during adolescence led to later deficits in cognition (see Schweinsburg *et al.*, 2008) and visual attention (Ehrenreich *et al.*, 1999), and was associated with decreases in educational achievement (Brook *et al.*, 2008). Furthermore, abstinent adolescent marijuana users exhibited deficits in sustained attention and working memory that were associated with altered hippocampal function as measured by functional magnetic resonance imaging (Jacobsen *et al.*, 2004). Similarly, treatment of rodents during adolescence with  $\Delta^9$ -tetrahydrocannabinol (THC) [the primary psychoactive constituent of marijuana; (Gaoni and Mechoulam, 1964)] produced altered cognition and emotionality in adulthood (Rubino *et al.*, 2008; Rubino *et al.*, 2009). Working memory and social interaction were also impaired in adolescent rats following 21 days of treatment with the cannabinoid agonist CP55,940, whereas adult animals showed no effect (O'Shea *et al.*, 2004). These data suggest that marijuana use during adolescence could produce immediate and long-term behavioural alterations, but do not provide a neural basis for these observations.

THC produces its CNS effects by binding to G-protein coupled cannabinoid type 1 (CB<sub>1</sub>) receptors (Howlett *et al.*, 2002; receptor nomenclature follows Alexander *et al.*, 2009). While CB<sub>1</sub> receptors are widely distributed in the brain at high density (Herkenham *et al.*, 1991), their expression can vary throughout life. For example, the expression of CB<sub>1</sub> receptors and mRNA increase from birth until adolescence whereupon they decrease to adult levels (Rodriguez de Fonseca *et al.*, 1993; McLaughlin *et al.*, 1994; Belue *et al.*, 1995). Consistent with these findings, the acute effects of THC differ somewhat between adolescents and adults for certain *in vivo* measures (Cha *et al.*, 2006; Wiley *et al.*, 2007). The issue is further complicated by reports that adult female rats are more sensitive to the locomotor and antinociceptive effects of cannabinoids than male rats (Tseng and Craft, 2001; Wiley, 2003). Taken together, these findings demonstrate the importance of considering both age and sex in evaluating the effect of cannabinoids on CB<sub>1</sub> receptor function.

CB<sub>1</sub> receptor density and G-protein activation are further altered by repeated cannabinoid treatment. Animal studies have shown that repeated THC administration results in region-specific down-regulation (loss of receptor number) and desensitization (attenuated receptor-mediated G-protein activity) of CB<sub>1</sub> receptors (Sim-Selley, 2003). The potential impact of these adaptations is supported by findings that repeated marijuana use also produces CB<sub>1</sub> receptor down-regulation in brains from human marijuana users (Villares, 2007). Surprisingly, little is known about the neurobiological changes that occur following THC exposure during adolescence, despite the prevalence of marijuana use among adolescents. Adolescence in rodents is typically defined as a 2 week period that occurs between postnatal day (PN) 28–42 (Spear, 2000), during which changes in both physical (growth spurt, puberty) and behavioural (increased risk taking, increased social interaction with same-aged rodents) domains are similar to those observed in human adolescents. The few studies that have examined the effect of THC treatment during adolescence on CB<sub>1</sub> receptors have provided conflicting results, showing reduced CB<sub>1</sub> receptor density and G-protein activity (Rubino *et al.*, 2008) or no effect (Ellgren *et al.*, 2007). However, differences in rat strains and treatment regimen complicate comparison of results. Moreover, these studies did not compare the effects of THC in adolescents directly with the effects in adult animals. Therefore, the purpose of this study was to determine the consequences of repeated THC administration on CB<sub>1</sub> receptor density and receptor-mediated G-protein activity in various brain regions from adolescent and adult, male and female Long-Evans rats. This is an important question because CB<sub>1</sub> receptor desensitization/down-regulation might disrupt receptor-mediated effects of the endocannabinoid system in adolescents using marijuana and inappropriate modulation of this highly adapting system during adolescence could have profound consequences in later life, especially if chronic exposure to THC disrupts normal CNS maturation.

## Methods

### Animals

All animal care and experimental procedures reported in this manuscript were in accordance with guidelines published in the *Guide for the Care and Use of Laboratory Animals* (National Research Council, 1996) and were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University. Adult (PN > 60) and

adolescent (PN 25) male and female Long-Evans rats, purchased from Harlan (Indianapolis, IN, USA), were housed one per cage. They were allowed to habituate to the animal facilities for at least 3 days before injections began. All animals were kept in a temperature-controlled (23°C) environment with a 12 h light/dark cycle (lights on at 0700 h). Rats were free fed and had free access to water.

### Chronic THC administration

THC was dissolved in a solution of Tween 80/saline (8: 92, v/v). Rats were injected i.p. twice daily (7:00 and 14:00) with THC (10 mg kg<sup>-1</sup>) or vehicle for 9.5 days (PN 30–39 and PN ~ 65–74 for adolescents and adults, respectively). Rats were killed by decapitation twenty-four hours after the final injection (PN 40 for adolescents and ~PN 75 for adults) and various brain regions were dissected, including prefrontal cortex, striatum (includes caudate putamen, nucleus accumbens and rostral globus pallidus), hypothalamus, hippocampus, ventral midbrain (includes ventral tegmental area and substantia nigra), periaqueductal gray (PAG) and cerebellum. Tissue was stored at -80°C until use.

### Agonist-stimulated [<sup>35</sup>S]GTPγS binding

Tissue was placed in 5 mL of cold membrane buffer (50 mM Tris-HCl, 3 mM MgCl<sub>2</sub>, 1 mM EGTA, pH 7.4) and homogenized. The samples were then centrifuged at 50 000× *g* at 5°C for 10 min. Supernatant was removed, and samples were resuspended in 5 mL of assay buffer A (100 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.2 mM EGTA, 50 mM Tris-HCl, pH 7.4). Protein concentration was determined by the Bradford protocol (Bradford, 1976). Before assay, membranes (2–8 μg of protein) were preincubated for 25 min with adenosine deaminase (3 mU mL<sup>-1</sup>) at 30°C in assay buffer. Concentration-effect curves were generated by incubating the appropriate amount of membrane protein (4–8 μg) in assay buffer B (assay buffer A plus 1.25 g L<sup>-1</sup> BSA) with CP55,940 (0.01–10 μM) in the presence of 30 μM GDP and 0.1 nM [<sup>35</sup>S]GTPγS in 0.5 mL volume at 30°C for 2 h. Basal binding was measured in the absence of agonist, and nonspecific binding was measured in the presence of 20 μM unlabelled guanosine 5'-3-O-(thio)triphosphate. The reaction was terminated by vacuum filtration through Whatman GF/B glass fiber filters, followed by two washes with 4°C Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency after 10 h extraction in econosafe 1 scintillation fluid.

### [<sup>3</sup>H]SR141716A binding

Membranes were prepared as described above. Saturation analysis was performed by incubating 12 μg

membrane protein with 0.2–3 nM [<sup>3</sup>H]SR141716A (CB<sub>1</sub> receptor antagonist) in assay buffer A + BSA (0.5 g L<sup>-1</sup>) in the presence or absence of 5 μM unlabelled SR141716A (to determine non-specific and total binding, respectively) for 90 min at 30°C. The reaction was terminated by vacuum filtration through Whatman GF/B glass fiber filter that was pre-soaked in Tris buffer containing 5 g L<sup>-1</sup> BSA (Tris-BSA), followed by three washes with 4 °C Tris-BSA. Bound radioactivity was determined by liquid scintillation spectrophotometry at 45% efficiency after extraction in ScintiSafe Econo 1 scintillation fluid.

### Data analysis

Data are reported as mean (±SEM) of at least six experiments, each performed in triplicate. Non-specific binding was subtracted from each sample. Net stimulated [<sup>35</sup>S]GTPγS binding was defined as agonist-stimulated minus basal [<sup>35</sup>S]GTPγS binding, and percent stimulation was defined as (net-stimulated/basal [<sup>35</sup>S]GTPγS binding) × 100%. Non-linear iterative regression analyses of agonist concentration-effect and saturation binding curves were performed with Prism 4.0 (GraphPad Software, Inc., La Jolla, CA). Separate age × sex ANOVAs were used to analyse E<sub>max</sub> values, mean percent desensitization and mean percent down-regulation for each region. Separate age × sex × treatment ANOVAs were used to analyse B<sub>max</sub> values for each region. Significant interactions revealed by ANOVAs were further analysed by Tukey *post hoc* tests (α = 0.05) to specify the nature of the differences.

### Materials

SR141716A and CP55,940 were provided by the Drug Supply Program of the National Institute on Drug Abuse (Rockville, MD, USA). All compounds were dissolved in ethanol. Guanosine 5'-3-O-(thio)triphosphate was purchased from Roche Diagnostics (Indianapolis, IN, USA). [<sup>35</sup>S]GTPγS (1150–1250 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA, USA). [<sup>3</sup>H]-SR141716A (44.0 Ci/mmol) was purchased from GE Healthcare (Chalfont St. Giles, UK). WIN 55,212-2, GDP, bovine serum albumin (BSA) and adenosine deaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA). Scintillation fluid (Econosafe 1) was purchased from Thermo Fisher Scientific (Waltham, MA, USA).

### Results

This study compared the effects of chronic THC or vehicle treatment for 9.5 days on CB<sub>1</sub> receptor density and G-protein activity in adolescent and

Table 1

Maximal CP55,940-stimulated G-protein activation ( $E_{\max}$ ) in membranes from various brain regions in vehicle-treated adolescent and adult rats of both sexes

Brain region	Female adolescents	Female adults	Male adolescents	Male adults
Prefrontal cortex [ $F(1,20) = 1.5, P = 0.2$ ]	185 (24)	146 (14)	131 (12)	134 (15)
Striatum [ $F(1,20) = 2.5, P = 0.1$ ]	183 (19)	148 (16)	158 (12)	180 (23)
Hypothalamus [ $F(1,20) = 0.3, P = 0.6$ ]	154 (13)	123 (17)	146 (9)	128 (7)
PAG [ $F(1,20) = 0.002, P = 0.96$ ]	148 (10)	130 (11)	153 (12)	134 (10)
Hippocampus [ $F(1,20) = 0.1, P = 0.7$ ]	167 (22)	114 (31)	198 (16)	159 (18)
Ventral midbrain [ $F(1,20) = 2.2, P = 0.1$ ]	139 (17)	154 (19)	204 (22)	161 (19)
Cerebellum [ $F(1,20) = 1.9, P = 0.2$ ]	264 (10)	261 (14)	242 (11)	269 (10)

$E_{\max}$  values for vehicle-treated rats of each age and sex are expressed as mean percent CP55,940-stimulated [ $^{35}\text{S}$ ]GTP $\gamma$ S binding (SEM). For all regions,  $E_{\max}$  values were not significantly different across age and sex. ( $F$  values for the age–sex interactions are presented in brackets in the leftmost column underneath the name of the region.)


PAG = periaqueductal gray.

adult male and female rats. Dosing began on PN 29 or >PN 60 for adolescent and adult rats, respectively, and brains were collected 24 h after the last injection. G-protein activation was assessed by measuring CP55,940-stimulated [ $^{35}\text{S}$ ]GTP $\gamma$ S binding whereas CB $_1$  receptor density was measured using [ $^3\text{H}$ ]SR141716A saturation binding. Tissue preparations from various brain regions were used to determine regional specificity of any treatment, age and sex effects. Basal [ $^{35}\text{S}$ ]GTP $\gamma$ S binding did not significantly differ across age and sex in any region following THC treatment (data not shown).

Table 1 shows the results of CP55,940-stimulated [ $^{35}\text{S}$ ]GTP $\gamma$ S binding assays on membranes prepared from various brain regions. The extent of G-protein activation ( $E_{\max}$ ) in vehicle-treated rats varied quite widely across brain region within rats of the same age and sex (e.g. 114% stimulation and 261% stimulation in hippocampus and cerebellum, respectively, of adult female rats). This regional variation in the magnitude of G-protein activation in vehicle-treated rats is in agreement with previous reports (Sim-Selley and Childers, 2002). Differences across groups in the same region also occurred (e.g. 167% stimulation and 114% stimulation in hippocampus for adolescent and adult females, respectively), but tended to be of lesser magnitude and none were statistically significant when analysed by region with age  $\times$  sex factorial ANOVAs ( $F$  values presented in Table 1). When compared with vehicle treatment in corresponding membranes from rats of the same age and sex, THC reduced G-protein activation (i.e. lower  $E_{\max}$  values) in all brain regions, but did not alter  $EC_{50}$  values (concentration of CP55,940 required to produce 50% of maximal stimulation), suggesting that THC-induced desensitization

of CB $_1$  receptors occurred throughout the brain in both adolescents and adults. Figure 1 shows concentration-response curves for CP55,940-stimulated [ $^{35}\text{S}$ ]GTP $\gamma$ S binding for two brain regions (hippocampus and cerebellum) in vehicle- or THC-treated rats of each sex and age.

In order to standardize THC-induced desensitization data across regions, desensitization in THC-treated rats was expressed as a percent of the maximal stimulation ( $E_{\max}$ ) of membrane homogenates from vehicle-treated rats separately for each region (Figure 2). Although regional differences in the magnitude of desensitization were evident, age and sex differences were also prominent. A consistent finding across most assessed brain regions [except the cerebellum:  $F(1,20) = 0.45, P > 0.05$ ] was that tissues from female adolescents exhibited significantly greater desensitization as compared with one or more of the other groups. Significant age  $\times$  sex differences in the magnitude of desensitization were observed in the prefrontal cortex [ $F(1,20) = 9.8, P = 0.005$ ], striatum [ $F(1,20) = 5.6, P = 0.028$ ], PAG [ $F(1,20) = 45.9, P < 0.001$ ], hippocampus [ $F(1,20) = 28.9, P < 0.001$ ], and ventral midbrain [ $F(1,20) = 7.7, P = 0.012$ ] (Figure 2A, B, D, E and F, respectively). Tukey *post hoc* tests on the interaction revealed that significantly greater desensitization occurred in female adolescent rats than in female adult rats in the prefrontal cortex, PAG, hippocampus, and ventral midbrain. Age differences were also observed for males in three of the four areas (prefrontal cortex, PAG and hippocampus), but in the opposite direction. Lesser desensitization was seen in male adolescent rats than in male adult rats. In addition to these age differences, significant sex differences occurred in each of these four regions and in the striatum, with




**Figure 1**

Concentration effect curves for CP55,940-stimulated [<sup>35</sup>S]GTP $\gamma$ S binding in tissues from cerebellum (top panels) and hippocampus (bottom panels) of adolescent and adult rats (left and right panels, respectively) of both sexes that had received vehicle or THC treatment.  $E_{\max}$  values for vehicle-treated rats are presented in Table 1.

desensitization being greater in female adolescent rats than in male adolescent rats. Interestingly, the only sex difference in adult rats was in the PAG where male adult rats exhibited greater desensitization than did female adult rats, an effect that was opposite to that seen in adolescent rats. However, the magnitude of this difference was small (albeit statistically significant). In the hypothalamus, the age–sex interaction was not significant; however, analysis of significant main effects of age [ $F(1,20) = 43.8, P < 0.001$ ] and sex [ $F(1,20) = 15.9, P < 0.001$ ] revealed that adolescents showed greater overall desensitization than adults and that females showed greater overall desensitization than males, respectively (Figure 2C). These findings are consistent with those obtained in other regions as described above. Finally, desensitization in the cerebellum did not significantly differ across age or sex (Figure 2G).

In order to determine the degree to which the observed desensitization was related to CB<sub>1</sub> receptor down-regulation, analysis of [<sup>3</sup>H]SR141716A saturation curves was conducted on membrane homogenates derived from selected brain regions (prefrontal cortex, striatum, hypothalamus and ventral mid-brain) [Table 2]. These regions were selected because they corresponded with regions most likely to be involved in mediation of pharmacological effects of

THC that we previously measured in rats that had received treatments identical to those used here (Wiley *et al.*, 2007). These effects included catalepsy (ventral midbrain/striatum), hypothermia (hypothalamus) and locomotor activity (multiple regions). In each of these regions, vehicle-treated adolescent rats of both sexes had significantly higher densities of CB<sub>1</sub> receptors than did vehicle-treated adult rats (Table 2). THC treatment produced significant decreases in  $B_{\max}$  across all regions in membranes derived from the brains of THC-treated adolescent and adult rats of both sexes (Table 2), although no change in the  $K_D$  value was seen as a result of THC treatment (data not shown). These results show that residual THC was not present in the membranes because the  $K_D$  value of [<sup>3</sup>H]SR141716A was unchanged. These findings suggest that repeated treatment with THC caused a decrease in the total density of CB<sub>1</sub> receptors in these brain regions, as has been reported previously (Breivogel *et al.*, 1999). Unlike the data obtained for [<sup>35</sup>S]GTP $\gamma$ S binding, however, the degree of THC-induced down-regulation ( $B_{\max}$  of THC-treated rats expressed as a percentage change from the  $B_{\max}$  of vehicle-treated rats of corresponding age and sex) did not significantly differ across sex or age (Table 2). These results suggest that the group



**Figure 2**

Desensitization, defined as decrease in maximal stimulation ( $E_{max}$ ) of CP55,940-stimulated [ $^{35}$ S]GTP $\gamma$ S binding in THC-treated tissue. Data are expressed as a percent decrease in the  $E_{max}$  value, compared with vehicle-treated tissue from rats of the corresponding age and sex, in membrane homogenates derived from THC-treated female and male adolescent and adult Long-Evans rats treated twice daily with 10 mg kg $^{-1}$  THC for 9.5 days. (A–G) Desensitization in the prefrontal cortex, striatum, hypothalamus, periaqueductal gray (PAG), hippocampus, ventral midbrain and cerebellum, respectively. Values represent mean ( $\pm$ SEM) percent desensitization for each group. \* Significant ( $P < 0.05$ ) age difference for adolescents versus adults of the same sex (based on age–sex interaction). # Significant ( $P < 0.05$ ) sex difference within a single age group (based on age–sex interaction). \$ Significant ( $P < 0.05$ ) main effect for age or sex without an accompanying significant interaction.

differences observed in the percent CB $_1$  desensitization were not entirely mediated by CB $_1$  receptor down-regulation. Because there were no significant differences in the percent CB $_1$  down-regulation between different sex/age groups in these four regions, [ $^3$ H]SR141716A binding assays with tissue from other brain regions were not conducted.

## Discussion

The primary goal of this study was to evaluate CB $_1$  receptor adaptation following repeated THC treat-

ment in adolescent versus adult male and female rats. Administration of THC produced CB $_1$  receptor desensitization and down-regulation in all four groups, consistent with previous studies conducted in adult male rodents (Breivogel *et al.*, 1999; Sim-Selley, 2003), but the relative level of desensitization varied by group. Overall, female adolescent rats were more sensitive to THC-induced desensitization. While these differences reached significance in only certain regions when compared with male adolescent or to female adult rats, the overall trend is evident across several brain regions. Interestingly, adolescent male rats were less sensitive to

Table 2

[<sup>3</sup>H]SR141716A  $B_{\max}$  values and % down-regulation in membranes from various brain regions in vehicle- and THC-treated adolescent and adult rats of both sexes

Brain region	Female adolescents			Female adults			Male adolescents			Male adults		
	Veh	THC	% DR	Veh	THC	% DR	Veh	THC	% DR	Veh	THC	% DR
Prefrontal Cortex	4.5 (0.15)	3.4 (0.18)	23% (5.8)	2.3 (0.13)	1.7 (0.09)	23% (6.5)	4.8 (0.11)	3.8 (0.14)	20% (3.2)	2.4 (0.09)	1.8 (0.17)	26% (5.0)
Striatum	3.4 (0.12)	2.8 (0.06)	17% (3.8)	1.8 (0.05)	1.5 (0.03)	16% (3.8)	4.1 (0.08)	3.4 (0.24)	18% (4.6)	2.0 (0.04)	1.6 (0.07)	20% (4.5)
Hypothalamus	5.5 (0.12)	2.9 (0.06)	47% (1.4)	3.8 (0.10)	1.9 (0.08)	50% (2.2)	5.4 (0.15)	3.0 (0.06)	44% (1.5)	2.7 (0.09)	1.5 (0.06)	45% (3.8)
Ventral midbrain	4.1 (0.08)	2.9 (0.08)	30% (2.5)	2.9 (0.04)	2.1 (0.05)	29% (2.3)	5.2 (0.19)	3.7 (0.15)	28% (3.6)	3.7 (0.14)	2.6 (0.09)	29% (2.9)

Each value in columns labelled 'Veh' and 'THC' represents mean  $B_{\max}$  value (SEM), expressed in pmol per mg of membrane protein. % DR = % down-regulation =  $B_{\max}$  value of THC-treated rats expressed as a percent of maximal CB<sub>1</sub> receptor binding ( $B_{\max}$ ) of vehicle-treated rats of corresponding age and sex. Age × sex × treatment ANOVAs followed by Tukey *post hoc* tests revealed that  $B_{\max}$  values for adolescents were significantly higher than those for adults, regardless of treatment, with age-treatment interaction terms (and associated probability levels) for each region as follows: [prefrontal cortex  $F(1,40) = 5.5$ ,  $P = 0.02$ ], [striatum  $F(1,40) = 4.5$ ,  $P = 0.04$ ], [hypothalamus  $F(1,40) = 9.4$ ,  $P = 0.004$ ], [ventral midbrain  $F(1,40) = 6.0$ ,  $P = 0.02$ ]. In addition, the main effects for treatment were significant, indicating that THC treatment decreased  $B_{\max}$  values in each region. In contrast, percent down-regulation for each region did not differ across age and sex.

THC-induced desensitization than were male adult rats in three brain regions (prefrontal cortex, PAG and hippocampus), albeit the magnitude of difference was much less than for females. Subsequent receptor binding experiments revealed that the greater desensitization seen in female adolescents and the decreased desensitization in male adolescents did not result from differences in down-regulation of CB<sub>1</sub> receptors in the regions examined.

A second major finding was that vehicle-treated female and male adolescent rats had higher expression of CB<sub>1</sub> receptors than adults in several brain regions examined, as is consistent with CB<sub>1</sub> receptor pruning that occurs over the course of adolescence (Rodriguez de Fonseca *et al.*, 1993). Interestingly, this difference did not reliably translate into greater receptor-mediated G-protein activation in vehicle-treated rats, suggesting that signalling may be less efficient in the brains of adolescent rats. In contrast, neither CB<sub>1</sub> receptor number nor their activation as determined using agonist-stimulated [<sup>35</sup>S]GTPγS binding differed between male and female adult rats. This result was somewhat surprising, given reports that female rats are more sensitive to the anti-nociceptive, memory and motor effects of THC (Tseng and Craft, 2001; Wiley, 2003; Cha *et al.*, 2007), and suggest that *in vivo* differences seen acutely might relate more to pharmacokinetic than pharmacodynamic factors (see also Tseng *et al.*, 2004), although possible sex differences in downstream signalling mechanisms cannot be excluded (see Auger, 2003; Zhang *et al.*, 2003). To date, age

differences in pharmacokinetics of THC between adolescent and adult rats have not been reported for either sex.

With the exception of the PAG, sex differences in CB<sub>1</sub> receptor desensitization following THC treatment were only present in adolescents, where females exhibited greater desensitization than males. In the PAG, male adults showed greater desensitization than female adults, an effect that was opposite to that seen in the PAG in adolescent males and females. To our knowledge, one other study has examined desensitization of CB<sub>1</sub> receptors throughout the brain immediately following THC treatment in adolescence (Rubino *et al.*, 2008). Despite some methodological differences (Sprague-Dawley rats, different THC regimen, autoradiographic analysis) the same overall conclusion was reached: CB<sub>1</sub> receptor desensitization was greater in female compared with male adolescent rats. In fact, in the previous report, desensitization was found in only four regions in male rats, despite the presence of regionally widespread down-regulation. Surprisingly, the age- and sex-dependent differences in the magnitude of CB<sub>1</sub> receptor desensitization were not reflected by *in vivo* studies from our laboratory in which rats received THC according to the regimen in this study (Wiley *et al.*, 2007) and then were assessed in a tetrad of tests in which psychoactive cannabinoids produce characteristic effects (reduction in spontaneous activity, anti-nociception, hypothermia and catalepsy; Martin *et al.*, 1991). In part, this disparity between *in vivo* and *in vitro* data

might be related to a floor effect because maximal tolerance (i.e. resulting in a small or absent effect) was observed in most of the *in vivo* assays. Further, the *in vivo* assessment did not include dependent variables that are likely to be mediated by some of the brain areas in which desensitization was observed to differ between adolescent and adult rats or between sexes in adolescent rats (e.g. cognitive tasks involving hippocampal functioning). Moreover, several factors that affect *in vivo*, but not *in vitro*, measures might have contributed to the discrepancy between the *in vivo* and *in vitro* effects of repeated dosing with THC. First, G-protein activation represents a relatively early signalling event. As many other downstream pathways affect *in vivo* responses, compensatory adaptation could occur in any of these signalling mechanisms. Additionally, *in vivo* activity results from the interaction of several receptors and anatomical regions, so that concomitant adaptations in non-cannabinoid receptor systems could also affect results.

The finding that female adolescent rats were more sensitive to CB<sub>1</sub> receptor desensitization suggests that their endocannabinoid system might differ somewhat from the other groups examined, but the mechanism(s) underlying enhanced THC-induced desensitization in female adolescents has not yet been identified. Ellgren *et al.* (2008) systematically evaluated endocannabinoid levels and CB<sub>1</sub> receptors in the striatum and prefrontal cortex of vehicle- and THC-treated male rats at early (PN 29), mid (PN 38) and late (PN 50) adolescence. Results in vehicle-treated rats revealed that the levels of the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG), as well as the density of CB<sub>1</sub> receptors, varied over the adolescent period, with different patterns emerging in different regions. For example, anandamide levels peaked in the nucleus accumbens at mid-adolescence, whereas 2-AG decreased in this region from early to mid-adolescence. In contrast, endocannabinoids were stable in the caudate-putamen over the period examined. CB<sub>1</sub> receptor density increased in the nucleus accumbens shell over adolescence, but decreased in the nucleus accumbens core and in the prefrontal cortex. Intermittent THC administration (1.5 mg kg<sup>-1</sup> given every 3 days) did not alter CB<sub>1</sub> receptor expression, probably because the dose was rather low (Ellgren *et al.*, 2007). The effect of THC on the endocannabinoids was complex, but the overall pattern was a perturbation in the normal ratio of anandamide to 2-AG in the nucleus accumbens (significant at mid adolescence) and prefrontal cortex (significant in late adolescence). The functional significance of this ratio has been shown in the adult striatum, where anandamide attenuated

the electrophysiological effects of 2-AG on GABA neurons via modulation of its synthesis by diacylglycerol lipase (Maccarrone *et al.*, 2008). These findings suggest that the immediate effects of THC treatment, such as desensitization and tolerance, could vary throughout adolescence due to its disruption of this ratio as well as to its direct effects on receptor expression and activation (as shown here). Moreover, the present study suggests that effects might be more pronounced in females, especially during certain developmental windows.

Studies in which the FAAH inhibitor URB597 was administered during adolescence provide further evidence that perturbation of anandamide during adolescence can have long lasting consequences (Marco *et al.*, 2009). Examination of brains from adult male rats that had received URB597 in adolescence revealed region-specific changes in CB<sub>1</sub> receptors that included reduced receptor expression in the caudate-putamen, nucleus accumbens, ventral tegmental area (VTA) and hippocampus, with no change in most other regions examined. The effects of THC might be further exacerbated by differences in THC pharmacokinetics based on age and/or sex. Following an acute injection of THC, previous research has shown that higher peak brain levels of THC and its major active metabolite, 11-hydroxy-THC, are observed in adult female rats than in males (Tseng *et al.*, 2004); however, this study did not measure the effects of THC after repeated administration, as was performed for the desensitization assessment reported here.

In conclusion, the present study showed age- and sex-dependent differences in the magnitude of CB<sub>1</sub> receptor desensitization following repeated treatment with THC. Adolescent female rodents consistently showed the greatest degree of desensitization across all regions, suggesting that teenagers, especially females, might be particularly sensitive to the effects of repeated marijuana use on the brain endocannabinoid system, although whether this enhanced desensitization reflects increased vulnerability to disruption or protective adaptation is still uncertain. Nevertheless, if CB<sub>1</sub> receptor desensitization and down-regulation occur in teenagers, as they do in rats, the consequences of chronic marijuana use during this critical window of synaptic maturation could have profound consequences in later life. In light of data from previous studies, increased susceptibility to desensitization in female adolescents might result from interactions between THC (and its metabolites) and endocannabinoids, but this area has not been well defined in either adolescent or adult models. Clearly further research is needed in this area, specifically to examine the mechanisms of differential age- and sex-dependent



sensitivity to THC-induced CB<sub>1</sub> receptor desensitization and to determine the temporal profile of repeated adolescent THC exposure on CB<sub>1</sub> receptor function immediately following treatment and in adulthood.

## Acknowledgements

This research was supported by the National Institutes of Health National Institute on Drug Abuse Grants DA-016644 and DA-014277.

## Conflict of interest

None.

## References

- Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. *Br J Pharmacol* 158 (Suppl. 1): S1–S254.
- Auger AP (2003). Sex differences in the developing brain: crossroads in the phosphorylation of cAMP response element binding protein. *J Neuroendocrinol* 15: 622–627.
- Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. *Neurotoxicol Teratol* 17: 25–30.
- Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248–254.
- Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. *J Neurochem* 73: 2447–2459.
- Brook JS, Stimmel MA, Zhang C, Brook DW (2008). The association between earlier marijuana use and subsequent academic achievement and health problems: a longitudinal study. *Am J Addict* 17: 155–160.
- Cha YM, White AM, Kuhn CM, Wilson WA, Swartzwelder HS (2006). Differential effects of delta9-THC on learning in adolescent and adult rats. *Pharmacol Biochem Behav* 83: 448–455.
- Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS (2007). Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. *Behav Pharmacol* 18: 563–569.
- Copeland J, Swift W (2009). Cannabis use disorder: epidemiology and management. *Int Rev Psychiatry* 21: 96–103.
- Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L *et al.* (1999). Specific attentional dysfunction in adults following early start of cannabis use. *Psychopharmacology (Berl)* 142: 295–301.
- Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. *Neuropsychopharmacology* 32: 607–615.
- Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH *et al.* (2008). Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. *Eur Neuropsychopharmacol* 18: 826–834.
- Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. *J Am Chem Soc* 86: 1646–1647.
- Herkenham M, Lynn AB, Johnson MR, Melvin LS, DeCosta BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci* 11: 563–583.
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA *et al.* (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* 54: 161–202.
- Jacobsen LK, Mencil WE, Westerveld M, Pugh KR (2004). Impact of cannabis use on brain function in adolescents. *Ann N Y Acad Sci* 1021: 384–390.
- Jager G, Ramsey NF (2008). Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. *Curr Drug Abuse Rev* 1: 114–123.
- Maccarrone M, Rossi S, Bari M, DeChiara V, Fezza F, Musella A *et al.* (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. *Nat Neurosci* 11: 152–159.
- McLaughlin CR, Martin BR, Compton DR, Abood ME (1994). Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. *Drug Alcohol Depend* 36: 27–31.
- Marco EM, Rubino T, Adriani W, Viveros MP, Parolaro D, Laviola G (2009). Long-term consequences of URB597 administration during adolescence on cannabinoid CB1 receptor binding in brain areas. *Brain Res* 1257: 25–31.
- Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK *et al.* (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. *Pharmacol Biochem Behav* 40: 471–478.

National Research Council (1996). *Guide for the Care and Use of Laboratory Animals*. National Academy Press: Washington, DC.

O'Shea M, Singh ME, McGregor IS, Mallet PE (2004). Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. *J Psychopharmacol* 18: 502–508.

Rodriguez de Fonseca F, Ramos JA, Bonnini A, Fernandez RJJ (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. *Neuroreport* 4: 135–138.

Rubino T, Vigano D, Realini N, Guidali C, Braida D, Capurro V *et al.* (2008). Chronic delta(9)-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. *Neuropsychopharmacology* 33: 2760–2771.

Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D *et al.* (2009). Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. *Hippocampus* 19: 763–772.

Schweinsburg AD, Brown SA, Tapert SF (2008). The influence of marijuana use on neurocognitive functioning in adolescents. *Curr Drug Abuse Rev* 1: 99–111.

Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. *Crit Rev Neurobiol* 15: 91–119.

Sim-Selley LJ, Childers SR (2002). Neuroanatomical localization of receptor-activated G proteins in brain. *Methods Enzymol* 344: 42–58.

Spear LP (2000). The adolescent brain and age-related behavioral manifestations. *Neurosci Biobehav Rev* 24: 417–463.

Tseng AH, Craft RM (2001). Sex differences in antinociceptive and motoric effects of cannabinoids. *Eur J Pharmacol* 430: 41–47.

Tseng AH, Harding JW, Craft RM (2004). Pharmacokinetic factors in sex differences in Delta 9-tetrahydrocannabinol-induced behavioral effects in rats. *Behav Brain Res* 154: 77–83.

Villares J (2007). Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. *Neuroscience* 145: 323–334.

Wiley JL (2003). Sex-dependent effects of delta 9-tetrahydrocannabinol on locomotor activity in mice. *Neurosci Lett* 352: 77–80.

Wiley JL, O'Connell MM, Tokarz ME, Wright MJ Jr (2007). Pharmacological effects of acute and repeated administration of {delta}9-tetrahydrocannabinol in adolescent and adult rats. *J Pharmacol Exp Ther* 320: 1097–1105.

Zhang L, Li PP, Feng X, Barker JL, Smith SV, Rubino DR (2003). Sex-related differences in neuronal cell survival and signaling in rats. *Neurosci Lett* 337: 65–68.